Found 64 matching trials
Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites PHASE2 This is a global, multi-centre, open-label, study of GSK2118436 conducted i...
Show More Location
GSK Investigational Site
Learn More & Join Trial
Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma PHASE1 Present clinical study will be conducted in China to evaluate the pharmacok...
Show More Location
Multiple Locations
Learn More & Join Trial
A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma PHASE3 The purpose of this study was to evaluate safety and efficacy of the combin...
Show More Location
California Cancer Associates for Research and Excellence
Learn More & Join Trial
Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer PHASE2 The goal of this clinical research study is to learn if durvalumab and tram...
Show More Location
University of Texas MD Anderson Cancer Center
Learn More & Join Trial
Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers PHASE2 This was a Phase II, open-label, non-randomized, multi-center study of oral...
Show More Location
Novartis Investigative Site
Learn More & Join Trial
Absolute Bioavialability of GSK1120212 PHASE1 A Phase I, single-center, open-label, single-persiod, combined single dose ...
Show More Location
GSK Investigational Site
Learn More & Join Trial
Pilot Study on Trametinib for Surgical Unruptured AVMs PHASE2 Arteriovenous malformation (AVM) is a tangle of abnormal vessels that can p...
Show More Location
University Health Network
Learn More & Join Trial
A Dose Escalation Study to Assess Safety of GSK2256098 (FAK Inhibitor) in Combination With Trametinib (MEK Inhibitor) in Subjects With Advanced Solid Tumors PHASE1 The purpose of this study is to assess the safety of combination treatment ...
Show More Location
GSK Investigational Site
Learn More & Join Trial
Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD). PHASE3 This was a two-arm, randomized, double-blind Phase III study of dabrafenib ...
Show More Location
Novartis Investigative Site
Learn More & Join Trial
Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, Trametinib PHASE2 The purpose of this Phase II clinical trial is to establish the safety and ...
Show More Location
Cook Children's Health Care System
Learn More & Join Trial